About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
2020
2019
02
Jun 2021
02:35 E.S.T.
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021
Read more
11
May 2021
13:05 E.S.T.
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
Read more
06
May 2021
14:28 E.S.T.
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
Read more
26
Apr 2021
15:06 E.S.T.
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 1, 2021
Read more
09
Apr 2021
00:00 E.S.T.
Cellectis Completes Sale of $47 million through its ATM program
Read more
29
Mar 2021
14:48 E.S.T.
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
Read more
Prev
1
2
3
4
Next